SouthernWorldwide.com – A groundbreaking injectable therapy is showing significant promise in combating one of the most aggressive forms of skin cancer, melanoma, with positive results observed over a five-year period.
This novel personalized mRNA cancer therapy, identified as intisomeran autogene, has been developed through a collaborative effort between Merck and Moderna. When administered in conjunction with the established cancer immunotherapy drug KEYTRUDA (pembrolizumab), it demonstrates a notable impact on patient outcomes.
The compelling findings from the phase 2b KEYNOTE-942 study were officially unveiled at the prestigious American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago on May 27.
After an extensive follow-up period of approximately five years, the combined therapeutic approach proved to be highly effective. It was found to reduce the risk of melanoma recurrence or death by an impressive 49% when compared to the use of pembrolizumab as a standalone treatment.
This analysis encompassed data from 157 patients who had been diagnosed with high-risk stage 3 and 4 melanoma. Crucially, these individuals had undergone surgical removal of their cancerous tumors. The study participants were divided into two distinct cohorts: one group received the innovative combination therapy, while the other received only pembrolizumab, as detailed in a recent press release.
The results unequivocally indicated that the group benefiting from the combination therapy experienced advantages that were not only substantial but also “sustained and durable over time,” highlighting the long-lasting efficacy of the treatment.
Intisomeran autogene is a sophisticated therapy designed with a unique approach. It is meticulously crafted based on specific mutations identified within a patient’s individual tumor. The fundamental aim is to educate the patient’s immune system, enabling it to recognize the distinct characteristics of cancer cells, thereby facilitating a more effective attack and elimination.
According to the researchers involved in the study, intisomeran has been characterized as “well-tolerated” by patients. Furthermore, its safety profile has been described as “manageable,” suggesting a favorable risk-benefit ratio.
The most frequently reported side effects associated with the personalized mRNA vaccine when combined with KEYTRUDA included common issues such as fatigue, pain at the injection site, chills, fever, and headache. Importantly, the researchers noted the absence of any new long-term safety concerns arising from the treatment, nor were there any severe vaccine-related adverse events reported.
This promising combination therapy is currently undergoing further rigorous evaluation. It has advanced to a phase 3 study, which represents the final confirmation stage of clinical trials, before potential broader approval.
In a statement released by Merck in January, Dr. Kyle Holen, Moderna’s senior vice president and head of development for oncology and therapeutics, emphasized the significance of the gathered data. He highlighted the “potential of a prolonged benefit” observed in patients diagnosed with resected high-risk melanoma, underscoring the therapy’s lasting impact.
“We are committed to continuing our investment in our oncology platform due to such encouraging outcomes,” Dr. Holen stated. “These results vividly illustrate the extensive potential of mRNA technology in the realm of cancer care.”
Dr. Marjorie Green, senior vice president and head of oncology, global clinical development at Merck Research Laboratories, also shared her perspective. She acknowledged that for a considerable number of patients battling stage 3 or 4 melanoma, there exists a “significant risk of recurrence following surgery.”
“Therefore,” Dr. Green added, “demonstrating the longer-term potential of intisomeran autogene and KEYTRUDA to mitigate the risk of recurrence for specific melanoma patients represents a truly meaningful milestone in cancer treatment.”
The companies have pointed to the encouraging five-year follow-up data as a strong indicator of success. They are also eagerly anticipating the results from the upcoming late-stage INTerpath trial, which is being conducted in collaboration with Moderna and is investigating the therapy’s efficacy across several other hard-to-treat cancers.
